Entera Bio Ltd. (NASDAQ: ENTX) reported a second-quarter net loss per share of $0.14, missing the consensus estimate of $0.08. The Tel Aviv-based biotechnology company posted a total net loss of $7.3 million for the quarter ended June 30, 2026, significantly wider than the $2.7 million loss in the same period last year. The miss was primarily driven by a $2.7 million non-cash fair value remeasurement of pre-funded warrants, rather than operational inefficiencies. Despite the earnings miss, Entera secured an oversubscribed $275 million private placement, providing sufficient capital to advance its lead candidate EB613 toward New Drug Application (NDA) submission through 2030.

The widening loss reflects increased investment in clinical development preparations. Research and development expenses rose to $3.2 million from $1.5 million year-over-year, attributable to materials and production costs for the EB613 Phase 3 program and activities under its collaboration with OPKO Health Inc. General and administrative expenses increased modestly to $1.4 million from $1.1 million. The company confirmed alignment with the U.S. Food and Drug Administration (FDA) on its registrational Phase 3 study design for EB613, an oral anabolic tablet for osteoporosis in postmenopausal women.

Financial Performance

As of June 30, 2026, Entera held cash and cash equivalents of $11.3 million and restricted cash of $7.1 million. Total assets stood at $19.5 million, up from $16.0 million at the end of 2025. The balance sheet includes a pre-funded warrants liability of $9.6 million, contributing to total liabilities of $12.2 million.

Capital Raise and Pipeline Progress

In July 2026, Entera closed a private placement yielding gross proceeds of approximately $275.0 million before deducting fees. The transaction was led by BVF Partners L.P., which was granted the right to designate two directors to the Board of Directors. Other participants included Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.

The net proceeds will fully support the Phase 3 registrational program of EB613 through the anticipated NDA submission. Additionally, funds will advance EB612, an oral peptide replacement tablet for hypoparathyroidism, into clinical trials with OPKO Health Inc., with an Investigational New Drug (IND) application intended for filing in the first half of 2027.

What the Numbers Show

The divergence between the reported earnings miss and the strategic progress highlights the impact of accounting treatments on biotech metrics. While the loss per share missed estimates due to the non-cash warrant charge, the operational burn rate increased by only $1.9 million, reflecting deliberate scaling of R&D activities. The substantial cash position post-raise provides a robust buffer for executing its multi-year clinical strategy without immediate reliance on additional equity markets.

Entera Bio Ltd. (NASDAQ: ENTX) announced on Aug. 04, 2026, that post-hoc data from its Phase 2 clinical trial of EB613 (oral PTH(1-34)) has been selected for two presentations at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting. This recognition underscores the scientific significance of the data, which demonstrates the anabolic effects of the oral tablet in postmenopausal women with osteoporosis at high risk for fracture. The presentations will take place October 9–12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts.

The most prominent of these is a Plenary Poster Presentation, a distinction reserved for highly ranked submissions selected by the ASBMR program committee for the Welcome Reception and Plenary Poster Session. This selection highlights the potential of EB613 to transform the standard of care by offering an oral alternative to injectable anabolic therapies. The second presentation will occur during Poster Session II.

Presentation Schedule

The abstract, titled "EB613, Oral PTH(1-34) Tablet, Shows Markedly Enhanced Anabolic Effects in Postmenopausal Women with Osteoporosis at High Risk of Fracture: Insights from Phase 2 Trial," focuses on a post-hoc sensitivity analysis. This analysis evaluated the relationship between baseline T-score severity and EB613’s effects on Bone Mineral Density (BMD) and Bone Turnover Markers (BTM) at 6 months. The original Phase 2 study (Tripto-Shkolnik 2024) randomized 161 postmenopausal women with low bone mass or osteoporosis to placebo or four EB613 dose levels.

Clinical Context and Next Steps

EB613 is being developed as the first oral, once-daily anabolic tablet treatment for osteoporosis. Current anabolic therapies require subcutaneous injection, limiting their adoption among eligible patients. The Phase 2 study met all primary and secondary endpoints without significant safety concerns, showing rapid dose-proportional increases in bone formation markers and reductions in resorption markers. Effects on trabecular and cortical bone were consistent with published data for subcutaneous teriparatide at the 6-month time point.

Building on these results, Entera plans to conduct a single, randomized, double-blind, placebo-controlled Phase 3 trial of EB613 in approximately 750 postmenopausal women with osteoporosis. This pivotal trial aims to support a potential New Drug Application (NDA) submission to the FDA for the treatment of women with postmenopausal osteoporosis.

What the Numbers Show

The selection of EB613 data for the Plenary Poster Session signals strong peer validation of its clinical profile ahead of Phase 3. With osteoporotic fractures costing $57 billion in 2018 and projected to reach $95 billion by 2040, the development of an oral anabolic therapy addresses a significant unmet medical need. The ability to demonstrate enhanced anabolic effects specifically in high-risk patients (baseline T-score ≤-2.5) suggests that EB613 may offer superior efficacy where it is most needed, potentially differentiating it from existing injectable options in future regulatory reviews.